|
Canada-0-MATTRESSES شركة الأدلة
|
شركة أخبار :
- Targeting ALK Rearrangements in NSCLC: Current State of the Art
Currently, six ALK-target agents have been approved to treat advanced ALK+ NSCLC, including crizotinib, alectinib, ceritinib, ensartinib, brigatinib, and lorlatinib These targeted agents induce durable responses and improve survival outcomes Treatment with ALK inhibitors is recognized as the standard of care for advanced ALK+ NSCLC
- Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non . . .
These results coupled with prolonged intracranial efficacy and absence of new safety signals represent an unprecedented outcome for patients with advanced ALK -positive NSCLC and set a new benchmark for targeted therapies in cancer
- Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients . . .
Abstract Background Treatment of advanced ALK + NSCLC has improved with increasingly effective ALK tyrosine-kinase inhibitors (TKIs) We report real-world treatment patterns and outcomes from the Italian ATLAS registry
- Real-world costs, treatment patterns, and clinical outcomes associated . . .
Plain language summary Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are cutting-edge treatments recommended for a subset of patients with advanced non–small cell lung cancer (NSCLC) However, real-world evidence on treatment patterns, costs, and outcomes remains limited This study used a large US insurance claims database to evaluate real-world outcomes for patients
- Optimizing treatment and sequencing strategies for maximal . . . - Springer
Objectives To identify optimal treatments and sequencing strategies that maximize efficacy, safety, and net health benefits (NHB, a comprehensive measure of safety and efficacy) for ALK-positive non-small-cell lung-cancer (NSCLC) Methods Related data from phase Ⅱ-Ш clinical trials targeting ALK-positive NSCLC was identified through a systematic search of PubMed, EMBASE, the Cochrane
- ALK inhibitors against resistance in non-small cell lung cancer: an 18 . . .
The review traces an 18-year evolution of ALK inhibitors in NSCLC treatment, detailing resistance mechanisms, treatment strategies, and advancements like combination therapies and fourth-generation inhibitors, offering a structured overview of the field's progress and future directions
- Frontline Treatment Decisions in ALK+ NSCLC - CancerNetwork
The treatment landscape for ALK-positive advanced non–small cell lung cancer (NSCLC) has been revolutionized by the availability of highly effective second- and third-generation ALK inhibitors, each offering distinct efficacy and toxicity profiles that influence treatment selection
- Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon . . .
Rearrangements involving the anaplastic lymphocyte kinase (ALK) gene are found in 3% to 7% of NSCLC 1 Multiple ALK inhibitors, including first generation (crizotinib), second-generation (ceritinib, alectinib, brigatinib, and ensartinib), and third-generation (lorlatinib) ALK inhibitors have exhibited robust efficacy in patients with advanced ALK-rearranged NSCLC 1 In this issue of the Journal
- ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients . . .
Background: Randomized trials have demonstrated that anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) can be safe and efficacious treatments for patients with ALK-positive advanced non-small-cell lung cancer (aNSCLC) However, their safety, tolerability, effectiveness, and patterns of use in real-world patients remain
|
|